Qili Qiangxin Capsule Combined With Sacubitril/Valsartan for HFrEF: A Systematic Review and Meta-Analysis

Qili Qiangxin Capsule Combined With Sacubitril/Valsartan for HFrEF: A Systematic Review and Meta-Analysis

Background: Heart failure with reduced ejection fraction (HFrEF) is a complex, chronic disease and is among the top causes of morbidity and mortality. Angiotensin receptor-neprilysin inhibitor drugs represented by sacubitril/valsartan are the key drugs for the treatment of HFrEF in western medicine,...

Full description

Bibliographic Details
Main Authors: Qian Xiang, Mengxi Wang, Yuhan Ding, Manlu Fan, Huaqin Tong, Jiandong Chen, Peng Yu, Le Shen, Xiaohu Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Pharmacology
Subjects:
Qili Qiangxin capsule
heart failure with reduced ejection fraction
ARNI
sacubitril/valsartan
systematic review
meta-analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.832782/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.832782/full

Similar Items